Market closed
Atossa Therapeutics/$ATOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Ticker
$ATOS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
ISIN
US04962H5063
Website
ATOS Metrics
BasicAdvanced
$127M
-
-$0.21
1.02
-
Price and volume
Market cap
$127M
Beta
1.02
52-week high
$1.71
52-week low
$0.55
Average daily volume
770K
Financial strength
Current ratio
12.672
Quick ratio
12.003
Management effectiveness
Return on assets (TTM)
-21.67%
Return on equity (TTM)
-34.87%
Valuation
Price to book
1.95
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-5.602
Growth
Earnings per share change (TTM)
-12.02%
3-year earnings per share growth (CAGR)
6.04%
What the Analysts think about ATOS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Atossa Therapeutics stock.
ATOS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATOS News
AllArticlesVideos
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewsWire·2 weeks ago
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewsWire·2 weeks ago
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Atossa Therapeutics stock?
Atossa Therapeutics (ATOS) has a market cap of $127M as of May 16, 2025.
What is the P/E ratio for Atossa Therapeutics stock?
The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of May 16, 2025.
Does Atossa Therapeutics stock pay dividends?
No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Atossa Therapeutics dividend payment date?
Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Atossa Therapeutics?
Atossa Therapeutics (ATOS) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.